Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07933653
NA

Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer Patients

Sponsor: First Affiliated Hospital of Guangxi Medical University

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and safety of oral thalidomide for the prevention of radiation-induced dermatitis (RID) in breast-conserving surgery patients receiving intensity-modulated whole-breast radiotherapy. This is a single-center randomized controlled trial. Female breast cancer patients aged \>18 and \<70 years after breast-conserving surgery scheduled for whole-breast intensity-modulated radiotherapy will be enrolled. Subjects will be randomized at a 1:1 ratio to the intervention group (thalidomide 75 mg orally every bedtime plus standard skin care) or the control group (standard skin care alone). The observation window is defined as from the start of first radiotherapy to 42 days after completion of last radiotherapy. RID will be assessed weekly according to CTCAE v5.0, and the maximum grade within the observation window will be recorded for each subject. The primary endpoint is the incidence of grade ≥2 RID within the observation window. Secondary endpoints include incidence of grade ≥3 RID, time-to-first-onset of grade ≥2 RID, RID-related symptoms (burning, pruritus, pulling pain, tenderness), quality-of-life measured by EORTC QLQ-C30 / QLQ-BR23. Treatment-emergent adverse events will be documented using CTCAE v5.0, with special attention to thalidomide-related toxicities such as somnolence, peripheral sensory neuropathy and thromboembolism. A total of 68 participants are planned for enrolment.

Official title: Thalidomide for Prevention of Radiation-Induced Dermatitis in Breast Cancer Patients After Breast-Conserving Surgery Receiving Radiotherapy: A Randomized Controlled Study

Key Details

Gender

FEMALE

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

68

Start Date

2026-11-12

Completion Date

2028-12-31

Last Updated

2026-11-12

Healthy Volunteers

No

Interventions

DRUG

Thalidomide tablets

Patients receive thalidomide 75 mg orally once every night at bedtime, starting from the first fraction of radiotherapy until completion of the last fraction of radiotherapy.

OTHER

Standard supportive care

All patients receive uniform standard skin care education and guidance for radiation field skin: wear loose fitting 100% cotton tops; avoid direct sunlight exposure to irradiated skin; keep irradiated skin dry, clean and well ventilated; avoid friction and scratching.

Locations (1)

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China